ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,445
-1,30%
Bitcoin
70 097,62
-1,89%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lantheus Holdings Inc (LNTH)

  7. Lantheus Holdings Inc (LNTH) Actualités

LNTH Lantheus Holdings Inc

80,70
-2,17 (-2,62%)
Après les heures de négociation
Dernière mise à jour : 23:30:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Lantheus Holdings Inc LNTH NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-2,17 -2,62% 80,70 23:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
82,49 80,58 82,92 80,70 82,87
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
21/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202422:43EDGAR2Form 8-K - Current report
15/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202422:30GLOBELantheus Announces Executive Appointments to Accelerate..
13/5/202423:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202423:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202417:19EDGAR2Form 144 - Report of proposed sale of securities
02/5/202413:00GLOBELantheus Reports First Quarter 2024 Financial Results
18/4/202414:00GLOBELantheus to Host First Quarter 2024 Earnings Conference Call..
11/3/202421:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202416:46EDGAR2Form 144 - Report of proposed sale of securities
06/3/202402:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202402:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202401:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202414:30GLOBELantheus to Present at the Leerink Partners Global Biopharma..
04/3/202423:44EDGAR2Form 144 - Report of proposed sale of securities
04/3/202414:30GLOBELantheus Announces the FDA Approval of DEFINITY® (Perflutren..
28/2/202414:30GLOBELantheus Announces Promotion of Amanda Morgan to Chief..
26/2/202414:30GLOBELantheus to Present at the TD Cowen 44th Annual Health Care..
22/2/202413:49EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202413:47EDGAR2Form 8-K - Current report
22/2/202413:00GLOBELantheus Reports Fourth Quarter and Full Year 2023 Financial..
15/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202416:18EDGAR2Form 144 - Report of proposed sale of securities
13/2/202414:30GLOBELantheus Announces Collaboration to Provide Novel Tau..
08/2/202414:00GLOBELantheus to Host Fourth Quarter and Full Year 2023 Earnings..
26/1/202413:59EDGAR2Form 8-K - Current report
23/1/202414:00EDGAR2Form 8-K - Current report
23/1/202413:45GLOBELantheus Announces CEO Succession Plan
18/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202418:05EDGAR2Form 144 - Report of proposed sale of securities
11/1/202414:00GLOBELantheus Announces Acceptance of its First-to-File ANDA for..
09/1/202414:00GLOBELantheus Expands Radiopharmaceutical Oncology Pipeline via..
09/1/202413:57EDGAR2Form 8-K - Current report
09/1/202413:55GLOBELantheus Reports Preliminary Fiscal Year 2023 Revenue
03/1/202414:30GLOBELantheus to Present at the 42nd Annual J.P. Morgan..

Dernières Valeurs Consultées

NASDAQ
LNTH
Lantheus
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés